Bristol-Myers Squibb (BMY) is back in focus after the European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for advanced Hodgkin lymphoma in the EU, alongside strong new Phase 3 oncology data.

Recent oncology updates, including the new EU approval for Opdivo plus AVD, come as the stock shows a 7.13% year to date share price return and a 24.21% one year total shareholder return. However, shorter term three month share price performance remains weak, suggesting sentiment is improving but not yet settled.

If you are looking beyond large pharmaceuticals and want more ideas tied to healthcare breakthroughs, it is worth scanning 39 healthcare AI stocks as a next step for further stock ideas.

So with BMY trading at US$57.27 and screens flagging a material intrinsic discount, are investors looking at a genuine value opportunity here or has the market already started to price in future growth?

Most Popular Narrative: 9% Undervalued

At a last close of $57.27 versus a widely followed fair value of $62.96, the current narrative frames Bristol-Myers Squibb as trading at a material discount while still baking in meaningful execution risk.

Recent operational streamlining (cost-cutting/profitability initiatives and targeted capital deployment) enables BMS to reinvest in clinical programs with high value potential while supporting disciplined margin improvement and free cash flow stability. Execution on global launches and commercial expansion (e.g., Cobenfy, Qvantig, Camzyos, Breyanzi, Reblozyl) into new geographies and therapeutic areas is accelerating revenue momentum and offsetting U.S. price pressures, which in turn creates a path for sustained future net margin and earnings growth.

Want to see what sits behind that 9% gap to fair value? The narrative leans on shifting revenue mix, higher margins and a richer future earnings multiple. Curious how those moving parts combine into that $62.96 number at a 7.11% discount rate?

Result: Fair Value of $62.96 (UNDERVALUED)

However, that fair value gap can quickly narrow if upcoming patent expiries on key drugs or tighter U.S. pricing pressure affect revenue and margins more than analysts expect.

Another View: What The P/E Ratio Is Saying

The narrative pins BMY as 9% below fair value, yet the current P/E of 16.1x is slightly higher than the US pharmaceuticals average of 15.3x and still below a fair ratio of 18.7x. That mix of modest premium to industry but discount to fair ratio raises a simple question: is the risk skewed more to upside or to downside from here?

Next Steps

Uncertain whether the balance of risks and rewards in this article feels compelling or cautious for you as an investor? You can evaluate the trade off yourself by reviewing the 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If this Bristol-Myers Squibb story has sharpened your thinking, do not stop here. Broaden your opportunity set with focused stock ideas built from clear fundamental data.

• Target potential mispricings by scanning companies that analysts flag as attractively valued using the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks highlighted for resilient yields in the 9 dividend fortresses.
• Protect your downside by checking companies screened for financial resilience through the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.